Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension
Open Access
- 1 July 2004
- journal article
- clinical trial
- Published by BMJ in British Journal of Ophthalmology
- Vol. 88 (7), 953-956
- https://doi.org/10.1136/bjo.2003.032979
Abstract
Background/aims: To evaluate the efficacy of brimonidine purite versus dorzolamide given twice daily in primary open angle glaucoma or ocular hypertensive subjects. Methods: In this double masked, multicentre, prospective, crossover comparison 33 subjects were randomised to brimonidine purite or dorzolamide for the first 4 week treatment period after a 4 week washout. Subjects began the opposite treatment for the second 4 week period after another 4 week washout. Intraocular pressure (IOP) was measured at 08:00 (trough) and 10:00, 18:00, and 20:00 hours after dosing at each baseline and at the end of each treatment period. Results: The baseline diurnal IOP was 22.9 (SD 2.8) for brimonidine purite and 22.2 (SD 2.4) mm Hg for dorzolamide. The trough IOP following 4 weeks of therapy was 21.0 (SD 3.7) for brimonidine purite and 21.0 (SD 3.1) mm Hg for dorzolamide (p = 0.90). The mean diurnal IOP was 19.3 (SD 3.1) for brimonidine purite and 19.8 (SD 2.4) mm Hg for dorzolamide (p = 0.46). Dorzolamide caused more ocular stinging upon instillation (n = 8) than brimonidine purite (n = 1) (p = 0.02). No statistical differences existed between groups for systemic adverse events. Conclusions: This study suggests that brimonidine purite and dorzolamide each given twice daily have similar efficacy in primary open angle glaucoma or ocular hypertensive subjects. However, a trend was observed at 10:00 of greater brimonidine purite efficacy compared with dorzolamide.Keywords
This publication has 22 references indexed in Scilit:
- Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence studyBritish Journal of Ophthalmology, 1998
- Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertensionOphthalmology, 1998
- A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamideOphthalmology, 1998
- The Safety and Efficacy of Switching Timolol Maleate 0.5% Solution to Timolol Hemihydrate 0.5% Solution Given Twice DailyJournal of Ocular Pharmacology and Therapeutics, 1998
- Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertensionSurvey of Ophthalmology, 1996
- Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: A review of safety, efficacy, dose response, and dosing studiesSurvey of Ophthalmology, 1996
- A Double-Masked, Randomized 1-Year Study Comparing Dorzolamide (Trusopt), Timolol, and BetaxololAmerican Journal of Ophthalmology, 1995
- Four-Week Safety and Efficacy Study of Dorzolamide, a Novel, Active Topical Carbonic Anhydrase InhibitorAmerican Journal of Ophthalmology, 1993
- Dose Response and Duration of Action of Dorzolamide, a Topical Carbonic Anhydrase InhibitorAmerican Journal of Ophthalmology, 1992
- A double‐masked crossover study comparing the effects of carteolol 1% and 2% on intra‐ocular pressureActa Ophthalmologica, 1987